Highly active relapse / reminent multiple sclerosis and okrelizumab after failure of alemtuzumab treatment

Abstract

The case report describes 15years period (2004-2019) of a woman with relapse remitting multiple sclerosis gradually cured by glatiramer acetate, demethyl fumarate, fingolimod, alemtuzumab and ocrelizumab. Both clinical and rediological status was stabilized during regular aplication of ocrelizumab in standardized scheme.

Keywords

• relapse remitting multiple sclerosis
• first line treatment, alemtuzumab, ocrelizumab